Rybelsus (semaglutide) Tablets, 3 mg, offer a groundbreaking oral treatment option for adults with type 2 diabetes. Developed by Novo Nordisk, this tablet is the first of its kind, providing an effective solution for enhancing blood sugar control alongside diet and exercise. The 3 mg dosage serves as the initial dose in the treatment regimen, helping patients transition effectively to higher maintenance doses.

Details and Features:

• Product Name: Rybelsus (semaglutide) Tablets
• Dosage Strength: 3 mg
• Quantity: 30 Tablets per bottle
• Usage: Oral administration
• Indication: Initial dose for type 2 diabetes management
• Features:
  • Convenient once-daily dosing
  • Innovative GLP-1 receptor agonist formulation
  • Enhances patient compliance with oral delivery

Mechanism of Action:

Semaglutide, the active ingredient in Rybelsus, is a GLP-1 receptor agonist that mimics the natural hormone GLP-1. It works by increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying. These actions combine to improve blood glucose levels and may also aid in weight reduction.

Directions for Use:

1. Dosing: Start with one 3 mg tablet orally once daily for 30 days before transitioning to higher doses.
2. Timing: Take on an empty stomach, at least 30 minutes before the first meal of the day with no more than 4 ounces of plain water.
3. Swallowing: Tablet should be swallowed whole—do not split, crush, or chew.
4. Consistency: Take at the same time each day for optimal results.
5. Follow-up: Transition to a higher dose after 30 days as directed by your healthcare provider.

Warnings:

• Thyroid Tumors: Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
• Pancreatitis: Monitor for symptoms of pancreatitis; discontinue if suspected.
• Renal Considerations: Caution in patients with renal impairment; monitor renal function.
• Hypersensitivity: Discontinue use if there's a suspected allergic reaction.
• Pregnancy and Nursing: Not recommended during pregnancy or breastfeeding.

Side Effects:

• Common: Nausea, vomiting, diarrhea, abdominal pain, and decreased appetite.
• Serious: Hypoglycemia (especially when combined with insulin or sulfonylureas), pancreatitis, acute kidney injury, and severe allergic reactions.

Rybelsus (semaglutide) Tablets 3 mg provide an accessible and effective entry point for type 2 diabetes management, empowering patients with an impactful oral therapy option that fits seamlessly into daily routines under guidance from healthcare providers.